摘要
目的观察玻璃体腔内注射康柏西普治疗糖尿病视网膜病变合并视网膜静脉阻塞性黄斑囊样水肿的疗效。方法回顾性分析2016年1月至2018年2月确诊为糖尿病视网膜病变合并视网膜静脉阻塞,且黄斑囊样水肿的患者65例,66只眼,分为2组。一组行患眼球后注射曲安奈德20 mg,33例,33眼,另一组行玻璃体腔内注射康柏西普0.05 ml,32例,33眼。观察治疗前及治疗后1 d、1周、2周、4周的最佳矫正视力和黄斑中心凹厚度的改变。结果所有患者治疗后均无明显并发症发生。与治疗前比较,曲安奈德治疗组仅在治疗后1周和2周时最佳矫正视力较治疗前提高、黄斑中心凹厚度下降,差异有统计学意义(P<0.05),余时间点均差异无统计学意义(P>0.05);康柏西普治疗组在治疗后1 d、1周、2周、4周时最佳矫正视力提高、黄斑中心凹厚度也下降,差异有统计学意义(P<0.05)。结论玻璃体腔内注射康柏西普治疗糖尿病视网膜病变合并视网膜静脉阻塞性黄斑水肿安全性高,起效时间短,降低黄斑区视网膜厚度明显。
Objective To observe the therapeutic effects of intravitreal injection of Conbercept on diabetic retinopathy(DR) complicated by retinal vein occlusion(RVO) and cystoid macular edema(CME).Methods The clinical dat about 65 patients(66 eyes) with diabetic retinopathy complicated by RVO and CME were diagnosed and treated in our hospital from January 2016 to February 2018 were retrospectively analyzed,who were divided into froup A and group B.The 33 patients in group A(33 eyes) were treated by retrobulbar injection with triamcinolone acetonide(TA) 20 mg,and the other 32 patients(33 eyes) in group B were treated by intravitreal injection with Conbercept 0.05 ml.The best corrected visual acuity(BCVA) and central foveal thickness(CFT) before and at 1 day,1 w, 2 w,4 w after treatment were observed and compared between the two groups.Results No significant complications were observed in all the patients after treatment. As compared with that before treatment, BCVA was significantly increased and CFT was significantly decreased at 1 w and 2 w after treatment in group A(P<0.05)and there was no significant difference in the other time points(P>0.05).Moreover the BCVA in group B was significantly increased and CFT was significantly decreased at 1 day, 1 w, 2 w, 4 w after treatment(P<0.05). In addition the therapeutic effects in group A were superior to those in group B.Conclusion Intravitreal injection of Conbercept to treat DR complicated by RVO and CME has higher safety and short onset time, which can reduce macular retinal thickness obviously.
作者
殷英霞
吴香丽
陈冬军
赵慧英
刘彦
陈建华
YIN Yingxia;WU Xiangli;CHEN Dongjun(Department of Ophthalmology,Beijing Geriatric Hospital,Beijing 100095,China)
出处
《河北医药》
CAS
2019年第11期1655-1658,共4页
Hebei Medical Journal
